29 February 2024
Fusion Antibodies plc
("Fusion" or the "Company")
Total Voting
Rights
Fusion Antibodies plc (AIM: FAB),
specialists in pre-clinical antibody discovery,
engineering and supply for both therapeutic drug and diagnostic
applications, announces that the issued share capital of the
Company at the date of this announcement comprises 60,990,564
ordinary shares of 4 pence each with one voting right per
share ("Ordinary Shares"). The Company does not hold any Ordinary
Shares in treasury. Therefore, the total number of Ordinary Shares
and voting rights in the Company is 60,990,564.
The above figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
Enquiries:
|
Fusion
Antibodies plc
|
www.fusionantibodies.com
|
|
Adrian Kinkaid, Chief Executive
Officer
Stephen Smyth, Chief Financial
Officer
|
Via Walbrook PR
|
|
|
|
|
Allenby Capital
Limited
|
Tel: +44 (0)20 3328
5656
|
|
James Reeve/Vivek Bhardwaj (Corporate
Finance)
Tony Quirke/Joscelin Pinnington (Sales and
Corporate Broking)
|
|
|
|
|
|
Shard Capital
Partners LLP
|
|
|
Damon Heath (Joint Broker)
|
Tel:
+44 (0)207 186 9952
|
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
|
|
Anna Dunphy
|
Mob: +44 (0)7876 741
001
|
|
|
| |
|
|
About Fusion
Antibodies plc
Fusion is a Belfast based contract research
organisation ("CRO") providing a range of antibody engineering
services for the discovery and development of antibodies for both
therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody design, generation, development,
production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and
sequencing, antibody humanisation using Fusion's proprietary
CDRx TM platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin
out from Queen's University Belfast. The Company's mission is to
enable pharmaceutical and diagnostic companies to develop
innovative products in a timely and cost-effective manner for the
benefit of the global healthcare industry.
Fusion Antibodies growth strategy is based on
combining the latest technological advances with cutting edge
science to deliver new platforms that will enable Pharma and
Biotech companies get to the clinic faster, with the optimal drug
candidate and ultimately speed up the drug development
process.